ANI Pharmaceuticals | ANIP - Operating Expenses


ANI Pharmaceuticals reported $562.3M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Canopy Growth CAD 87.2M 6.22M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Perrigo USD 935.6M 89.6M Mar/2026
Sun Pharmaceuticals INR 114.07B 2.96B Dec/2025
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026